Interview with Rubens Lima, General Manager, Ipsen Brazil
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
Address: Av. Luis Carlos Berrini, 1297 cj 61 – Cidade Monções São Paulo – SP – CEP: 04571-010 Brasil,Brazil
Tel: -5693
Web: http://www.ipsen.com/en/ipsen-worldwide
Ipsen is a group that operates in the global biotechnology and pharmaceutical innovation in medical specialties with more than 20 in the world market. The Ipsen Group has a worldwide staff of about 4,000 employees. Its development strategy is based on a combination of special medicines in several therapeutic areas (oncology, endocrinology, neurology and hematology) and primary care products. The company has four R & D centers (Paris, Boston, Barcelona and London) and has a group of highly qualified researchers. More than 900 people in R & D are dedicated to the discovery of innovative medicines. This strategy is also supported by an active policy of partnerships of the Ipsen Group.
In 2010, total revenue was € 1.1 billion (USD $ 1.6 billion). Ipsen invested approximately € 220 million (USD $ 315 million, or 20% of consolidated sales) on research and development (a larger percentage of the global pharmaceutical industry). Ipsen has an extensive and sophisticated R & D program, which includes about 20 lines of research, from preclinical to Phase III.
The company’s clinical trials in Brazil are conducted in partnership with major research centers like the University of São Paulo (USP), Federal University of Rio de Janeiro (UFRJ), Universidade de Brasília (UnB) and Catholic University of Porto Alegre.
Dysport ® (Botulinum toxin type A, 500U, for the treatment of dystonias, spasticity and cosmetic uses), Somatuline ® Autogel ® (lanreotide for the treatment of acromegaly and neuroendocrine tumors), Apokyn ® (apomorphine for the treatment of the syndrome. advanced Parkinson’s), Nutropin ® (growth hormone) and INCRELEX ® (IGF-1 for the treatment of growth deficits).
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
Fernando Silveira F°, country manager in Brazil of ISDIN, documents the successful market entry and rapid development of this dermatology focused company in Brazil, while ISDIN has managed to establish…
Luis Fernando Lenski, head of South Cone and general manager of Galderma Brazil, provides insights into the affiliate’s heightened and tireless efforts in terms of medical education and his focus…
Juan Pablo Udry, general manager Brazil and Latin America at Boiron, the world’s undisputed leader in homeopathic medicines, provides an insightful overview of the Brazilian and Latin American landscape for…
Cesar Rengifo, senior vice president and area director Emerging Markets West at GSK, the fastest growing multinational company in both Brazil and Latin America, discusses the perfect match between GSK’s…
Ivo Mafra, president and founder of DC Logistics Brazil, a Brazilian based third party logistics (3PL) company awarded Best partner Worldwide and Latin America 2016 – WCA world, details the…
Alex Carvalho, general manager Pierre Fabre Brazil, provides insights into the rapidly ascending trajectory of the company in Brazil, its utmost commitment to oncology in the country, and Pierre Fabre’s…
Leandro Pinheiro Safatle, executive secretary of the Brazilian Drug Market Regulation Chamber (CMED) explains why pharmaceuticals was the only sector to have resisted the country’s recent recession, the role that…
Gaetano Crupi, president and general manager of BMS in Brazil, leverages his long-standing experience at the head of prestigious pharmaceutical companies’ affiliates to provide an insightful overview of the key…
Fraser Hall, country president of AstraZeneca Brazil, describes the current trends and dynamics shaping the Brazilian pharmaceutical market and documents the promising partnership opportunities he envisions to significantly increase patient…
Sameer Savkur, country manager of Biogen Brazil, provides insights into the key specificities of the Brazilian pharmaceutical ecosystem and documents the great successes of Biogen affiliate in working hand-in-hand with…
Dr. Florentino Cardoso, president of the Brazilian Medical Association, discusses the challenges of navigating Brazil’s healthcare system and reveals his aim to promote the needs of the medical community to…
Henrique Tada, executive director of ALANAC, the association gathering Brazilian pharmaceutical companies, provides an historical overview of the rapid and eye-catching growth of the local pharmaceutical industry and documents the…
See our Cookie Privacy Policy Here
